Funding for this research was provided by:
Prilenia Therapeutics Ltd (----)
Fundação Luso-Americana para o Desenvolvimento (FLAD Life Science 2020)
Fundo Regional para a Ciência e Tecnologia (CENTRO-01-0145-FEDER-000012- HealthyAging2020)
Fundação para a Ciência e a Tecnologia (POCI-01-0145-FEDER-007440, UIDB/04539/2020)
Accepted: 31 January 2021
First Online: 1 April 2021
: All mouse experiments were carried out in accordance with the guidelines of the Institutional Animal Care and Use of Committee and the European Community directive (2010/63/EU) and protocols approved by the Faculty of Medicine, University of Coimbra (ref: ORBEA_189_2018/11042018) and UBC Committee (ref A16-0130) on Animal Care and the Canadian Council on Animal Care. All efforts were made to minimize animal suffering and to reduce the number of animals used.
: All authors read and agreed to publish the present manuscript in its current format.
: MG and MH were employed by Teva Pharmaceutical Industries Ltd (transferred rights to Prilenia Therapeutics Ltd) during the time this study was conducted. LN and CM received a post-doctoral and a research grant, respectively, financed by Teva Pharmaceutical during part of the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Free to read: This content has been made available to all.